![]() |
|||||||||||||||||
![]() |
|||||||||||||||||
![]() ![]() ![]() |
![]() |
|
|||||||||||||||
![]() |
![]() |
MATERIAL SAFETY DATA SHEET - INFECTIOUS SUBSTANCES SECTION I - INFECTIOUS AGENT NAME: Mycoplasma pneumoniae; M. hominis SYNONYM OR CROSS REFERENCE: Mycoplasmal pneumonia, pleural atypical pneumonia, PPLO, pleuropneumonia-like organisms CHARACTERISTICS: Gram-negative pleomorphic cells, smaller than conventional bacteria (0.2-2µm), parasitic and saprophytic in existence; spherical to ovoid shaped, atypical pathoghen, single triple-layered membrane but lacking true cell wall; intracellular localization; terminal organelle that plays a role in attachment SECTION II - HEALTH HAZARD PATHOGENICITY: Mucosally associated, respiratory and urogenital tract localization, rarely penetrates the submucosa; M. hominis - potential pathogen of reproductive tract, common parasite of lower urogenital tract; can disseminate to other parts (particularly in the immune-compromised), acute pyelonephritis caused by invasion of the upper urinary tract; cerebrospinal fluid invasion; invasive disease of the joints, respiratory tract with bacteremia; can cause sternal infection; vertical transmission (18-55%) causes congenital pneumonia, bacteremia, progression to chronic lung disease or prematurity; M. pneumoniae - Comprises 15-20% of all pneumonia cases; febrile lower respiratory infection; less often a pharyngitis progressing to bronchitis or pneumonia; non-pulmonary manifestations including neurologic, hepatic, cardiac and hematologic disorders; gradual onset with headache, malaise, paroxysmal cough, substernal pain; leukocytosis in some cases; duration varies from a few days to a month or more; Low fatality EPIDEMIOLOGY: Worldwide; M. pneumoniae - sporadic, endemic and occasionally epidemic in institutions and military; greatest during fall and winter months in temperate climates; all ages but asymptomatic or mild in children under 5 years of age HOST RANGE: Humans, non-human primates INFECTIOUS DOSE: Not known MODE OF TRANSMISSION: By droplet inhalation, direct contact with infected persons or with freshly soiled articles from an acutely ill and coughing patient; secondary cases among contacts are frequent INCUBATION PERIOD: Six to 23 days COMMUNICABILITY: Communicable period is less than 10 days; occasionally longer with persisting febrile illness or persistence of organism in convalescence SECTION III - DISSEMINATION RESERVOIR: Humans ZOONOSIS: None VECTORS: None SECTION IV - VIABILITY DRUG SUSCEPTIBILITY: M. hominis - Sensitive to tetracyclines, gentamicin, doxycycline, aminoglycosides, macrolides, clindamycin; M. pneumoniae - fluroquinolone, trovafloxacin, moxifloxacin DRUG RESISTANCE: Innate resistance to penicillins and rifampicins; tetracycline resistance due to acquisition of tetM gene; M. hominis - resistance to erythromycin and azithromycin have been reported SUSCEPTIBILITY TO DISINFECTANTS: Sensitive to many disinfectants - 1% sodium hypochlorite, 70% ethanol, glutaraldehyde, formaldehyde PHYSICAL INACTIVATION: Sensitive to drying, moist heat (121° C for at least 15 min) and dry heat (160-170° C for at least l hour) SURVIVAL OUTSIDE HOST: Air (10% RH) - 50 h; Air (90% RH) - 20 h; Air (30-80% RH) - <10 h) SECTION V - MEDICAL SURVEILLANCE: Monitor for symptoms; confirm bacteriologically FIRST AID/TREATMENT: Antibiotic therapy IMMUNIZATION: None PROPHYLAXIS: Antibiotic prophylaxis SECTION VI - LABORATORY HAZARDS LABORATORY-ACQUIRED INFECTIONS: 4 reported cases up to 1976 SOURCES/SPECIMENS:Blood, synovial fluid, amniotic fluid, cerebrospinal fluid, urine, prostatic secretions, semen, wound aspirates, sputum, pleural fluid, bronchoalveolar lavage specimens; swabs from nasopharynx, cervix, vagina, wounds and urethra PRIMARY HAZARDS: Droplet exposure of mucous membranes; infectious aerosols; parenteral inoculation, ingestion SPECIAL HAZARDS: None SECTION VII - RECOMMENDED PRECAUTIONS CONTAINMENT REQUIREMENTS: Biosafety level 2 practices, containment equipment and facilities for all activities involving clinical materials or cultures; additional precautions and containment for activities with high potential for aerosol production PROTECTIVE CLOTHING: Laboratory coat; gloves when direct contact with infectious materials is unavoidable; gown (tight wrists and ties in back) and gloves for work in biosafety cabinet OTHER PRECAUTIONS: None SECTION VIII - HANDLING INFORMATION SPILLS: Allow aerosols to settle; wear protective clothing; gently cover spill with paper towels and apply 1% sodium hypochlorite, starting at perimeter and working towards the centre; allow sufficient contact time (30 min) before clean up DISPOSAL: Decontaminate before disposal - steam sterilization, chemical disinfection, incineration STORAGE: In sealed containers that are appropriately labelled SECTION IX - MISCELLANEOUS INFORMATION Date prepared: March, 2001 Prepared by: Office of Laboratory Security, PHAC Although the information, opinions and recommendations contained in this Material Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date. Copyright © [Material Safety Data Sheets - Index]
|
![]() |
|||
![]() |
Last Updated: 2001-05-15 | ![]() |